Articles

Global Osteogenesis Osteogenesis Imperfecta Treatment Market, by Drugs by Route of Administration and by Region: Size, Share, Outlook and Opportunity Analysis, 2023 – 2030

Osteogenesis imperfecta is a genetic disease that affects the bones and also prevents the body from building strong bones.

This disease makes bones brittle and breaks easily without any cause.

Osteogenesis Imperfecta is referred to as imperfect bone formation, and people who suffer from this disorder have bones that fracture or break easily.

Introduction

Osteogenesis Imperfecta is commonly known as brittle bone disease. In severe cases, multiple fractures are common, while a milder case involves a few fractures or broken bones in a person's lifetime. People with this condition are born unable to produce connective tissue or have it due to faulty genes. It impacts the synthesis of collagen, the connective tissue protein that strengthens bones. The disease occurs in forms I and IX, with I being mild and IX being fatal. The main sign of osteogenesis imperfecta is frequent fractures. Other symptoms include loose joints, deformed bones, hearing loss, breathing problems and dental problems. Osteogenesis imperfecta can be confirmed through DNA or collagen testing.

Treatments

There is no treatment for this because it is a genetic condition. Exercise and quitting smoking are two examples of healthy lifestyle choices that can help prevent fractures. Braces, painkillers, and proper care of bone fractures are all helpful. Antibiotics and antiseptics can be used to treat bone infections. Increasing demand for new therapies for the treatment of osteogenesis imperfecta and licensing agreements and strategic collaborations by key industry players for treatment development are expected to propel the growth of the global osteogenesis imperfecta treatment market in forecast period.

Market dynamics

Increasing research and development funding to develop new treatments and therapies is an important factor spurring the growth of the global osteogenesis imperfecta treatment market. Furthermore, licensing agreements and strategic collaborations by major industry players for the development of OI treatment are another factor driving the growth of the market. Furthermore, osteogenesis imperfecta is a genetic disease, and the family history of people with OI is causing an increase in the number of cases worldwide, which is expected to drive market growth.

For example, in May 2021, Mereo BioPharma Group plc announced encouraging 6-month data from its Phase II-B clinical trial in adult patients with osteogenesis imperfecta type IV, III or I treated with setursumab (BPS-804). The European Medicines Agency (EMA) had approved the company's pediatric investigation plan for BPS-804 and with a registration study design, and the drug candidate is now ready for Phase III for a pediatric population.

Main features of the study:

This report provides in-depth analysis of the global Osteogenesis Imperfecta Treatment market and provides the market size (USD Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It clarifies the potential income opportunities in different segments and explains the attractive investment proposition matrices for this market
This study also provides key insights into market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Profiles key players in the global Osteogenesis Imperfecta Treatment market based on the following parameters: Company Highlights, Product Portfolio, Key Highlights, Financial Performance, and Strategies
The major companies covered under this study are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd. , Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
The insights from this report will enable marketers and management authorities of companies to make informed decisions regarding their future product launches, type upgrading, market expansion and marketing tactics.

The global Osteogenesis Imperfecta Treatment market report addresses various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts:

Stakeholders would have ease in decision making through various strategic matrices used in the analysis of the global Osteogenesis Imperfecta Treatment market.